Literature DB >> 15218971

EBV-positive Burkitt lymphoma as a late-onset posttransplantion lymphoproliferative disorder after allogeneic stem cell transplantation.

Naohiro Sekiguchi1, Junko Nishimoto, Ryuji Tanosaki, Nobuko Kubota, Yukiko Yokota, Yukio Kobayashi, Takashi Watanabe, Masahiro Kami, Yoichi Takaue, Yoshihiro Matsuno, Kensei Tobinai.   

Abstract

Posttransplantation lymphoproliferative disorder (PTLD) is one of the well-recognized complications after allogeneic stem cell transplantation (SCT). It generally occurs early after SCT, and only a few reports of late-onset cases are available. We report a 58-year-old male patient who developed lymphoma 4 years after allogeneic SCT for chronic myeloid leukemia. The presence of c-myc translocation and Epstein-Barr virus-encoded RNA in the lymphoma cells, without rearrangement of the 3'-bcr region, confirmed the histopathologic diagnosis of Burkitt lymphoma. DNA chimerism analysis revealed that the lymphoma cells were of donor origin. The patient achieved complete response with intensive chemotherapy. To our knowledge, this is the first report of Burkitt lymphoma as a PTLD occurring after allogeneic SCT.

Entities:  

Mesh:

Year:  2004        PMID: 15218971     DOI: 10.1532/ijh97.03175

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  9 in total

1.  The Spectrum of AIDS-Related Lymphoproliferative Disorders.

Authors: 
Journal:  Adv Clin Path       Date:  1997-01

2.  Statins as a newly recognized type of immunomodulator.

Authors:  B Kwak; F Mulhaupt; S Myit; F Mach
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

3.  Do statins cause cancer? A meta-analysis of large randomized clinical trials.

Authors:  L M Bjerre; J LeLorier
Journal:  Am J Med       Date:  2001-06-15       Impact factor: 4.965

4.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.

Authors:  R E Curtis; L B Travis; P A Rowlings; G Socié; D W Kingma; P M Banks; E S Jaffe; G E Sale; M M Horowitz; R P Witherspoon; D A Shriner; D J Weisdorf; H J Kolb; K M Sullivan; K A Sobocinski; R P Gale; R N Hoover; J F Fraumeni; H J Deeg
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

5.  Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?

Authors:  B P Nelson; M A Nalesnik; D W Bahler; J Locker; J J Fung; S H Swerdlow
Journal:  Am J Surg Pathol       Date:  2000-03       Impact factor: 6.394

6.  Late onset post-transplantation lymphoproliferative disease of recipient origin following cytogenetic relapse and occult autologous haematopoietic regeneration after allogeneic bone marrow transplantation for acute myeloid leukaemia.

Authors:  W Y Au; A K Lie; C K Lee; S K Ma; T S Wan; T W Shek; R Liang; Y L Kwong
Journal:  Bone Marrow Transplant       Date:  2001-08       Impact factor: 5.483

7.  Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.

Authors:  I Magrath; M Adde; A Shad; D Venzon; N Seibel; J Gootenberg; J Neely; C Arndt; M Nieder; E Jaffe; R A Wittes; I D Horak
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

8.  Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases.

Authors:  Jerald Z Gong; Timothy T Stenzel; Ellen R Bennett; Anand S Lagoo; Cherie H Dunphy; Joseph O Moore; David A Rizzieri; James H Tepperberg; Peter Papenhausen; Patrick J Buckley
Journal:  Am J Surg Pathol       Date:  2003-06       Impact factor: 6.394

Review 9.  Carcinogenicity of lipid-lowering drugs.

Authors:  T B Newman; S B Hulley
Journal:  JAMA       Date:  1996-01-03       Impact factor: 56.272

  9 in total
  1 in total

1.  The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells.

Authors:  Chuntuan Li; Pengliang Xin; Huifang Xiao; Yan Zheng; Yuanling Huang; Xiongpeng Zhu
Journal:  Cancer Cell Int       Date:  2015-06-24       Impact factor: 5.722

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.